GlassScriptPhysician profile
Srikanth Mitta
NPI 1447316708
$395.64
in general payments reported to CMS, 2019-2025
13 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.94 · 2021: $28.47 · 2022: $79.39 · 2023: $44.09 · 2024: $114 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $259.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $55.49 | 2020-2024 | Zepbound |
| Amryt Pharma Holdings LTD | $55.35 | 2022 | |
| Beta Bionics, INC. | $53.41 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $53.38 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $29.78 | 2021-2024 | Rybelsus, Ozempic |
| Ascendis Pharma Endocrinology INC | $27.89 | 2025 | Yorvipath |
| Abbott Laboratories | $23.04 | 2024 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $20.89 | 2023 | Isturisa, Signifor Lar |
| Insulet Corporation | $19.69 | 2024 | Omnipod |
| Sequel Med Tech, LLC | $18.02 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.11 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 | |
| Strongbridge US INC. | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srikanth Mitta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.